GHRS GH Research PLC
$27.20▼ -0.29%
Healthcare
Other
After hours
$26.70▼ -1.83%
Sep 11, 7:30 PM ET
Volume 159.2K
Avg Volume (10D) 179.9K
Key Metrics & Fundamentals
Market Cap
$1.87B
P/E Ratio
–
Div Yield
–%
52W Range
11.83 - 31.44
% vs 50 MA
-3.44%
% vs 200 MA
35.32%
RSI-14
43.3
MACD Histogram
-0.1900
Beta (1Y vs SPY)
1.49
Free Cash Flow
-$15.04M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$18.39M
COGS
–
Operating Exp
$19.45M
Operating Income
-$19.45M
EBIT
-$19.45M
Pretax Income
-$15.15M
Net Income
-$15.15M
EPS (Diluted)
-0.23
Price & Volume History
Loading chart…
Recent News
Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight
PR Newswire · Aug 25, 2026 2:31 PM
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · Aug 6, 2026 11:00 AM
Is GH Research (GHRS) Trading At A Premium To Fair Value?
Simply Wall St. · Aug 2, 2026 6:09 PM
CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners
Stocktwits · Jul 27, 2026 2:38 PM
Wells Fargo Initiates GH Research at Overweight With $44 Price Target
MT Newswires · Jul 27, 2026 12:12 PM
Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug
24/7 Wall St. · Jul 16, 2026 5:53 PM
Why Psychedelic stocks are surging today
Investing.com · Jul 16, 2026 11:44 AM
GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS)
InvestorsHub · Jul 16, 2026 10:33 AM
The Race to Commercialize the World’s Most Powerful Psychedelic
WSJ · Jul 14, 2026 7:00 PM
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
Proactive · Jul 13, 2026 6:59 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See GHRS's money flow as a full page
Social Sentiment
Avg +0.84 · 8 posts
NewsDiscussionTrump just signed an EO to fast-track psychedelics. ATAI ($1.4B) and GHRS ($1.04B) are Phase 3-ready with FDA Breakthrough designations.
r/wallstreetbets · Apr 18, 2026
GH Research is highlighted as a key beneficiary of the FDA's fast-tracking initiative.
very_positive
+1.00
Something’s gotta give. Any thoughts?
r/stocks · Dec 18, 2025
The author expresses a positive view of GHRS, citing potential upside and a long-held position, indicating a bullish sentiment.
positive
+0.30
DDPriceTargetA neuroscientist's prediction: GHRS will go to the moon
r/wallstreetbets · Sep 22, 2025
The author believes GHRS presents a 'golden opportunity' and predicts it will 'go to the moon'.
very_positive
+0.90
DDNewsTradePsychedelic DD: A Trip to the Moon
r/wallstreetbets · Jul 18, 2025
The post strongly advocates for $GHRS as a major psychedelic stock play due to recent developments.
very_positive
+1.00
DDNewsPsychedelic DD: A Trip to the Moon
r/wallstreetbets · Jul 18, 2025
The post strongly advocates for $GHRS as a 'next big pharma bet' due to government backing and trials.
very_positive
+1.00
Page 1 of 2 (8 total)
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.